Birth of the incretin concept The same year Lim and Kosaka published their hypothesis, the Belgian physiologist La Barre attempted to purify secretin with Eugene Still, a colleague at the University of Chicago
Los medicamentos GLP-1 aprobados por la FDA, como semaglutida (Ozempic, Wegovy) y liraglutida (Victoza, Saxenda), producen aumentos farmacolgicos sostenidos en la actividad del receptor de GLP-1, resultando en reducciones de hemoglobina A1c de 1.0-1.5% y prdida de peso de 10-15% o ms
This mechanism explains the rapid rise of GLP-1 weight loss treatments in metabolic medicine
For weight loss, the main options are Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide)
Supporting this level of demand requires more than simply increasing batch size